| Title |
Clinical development of insulin-like growth factor receptor—1 (IGF-1R) inhibitors: At the crossroad?
|
|---|---|
| Published in |
Investigational New Drugs, March 2012
|
| DOI | 10.1007/s10637-012-9811-0 |
| Pubmed ID | |
| Authors |
Andrea Gombos, Otto Metzger-Filho, Lissandra Dal Lago, Ahmad Awada-Hussein |
| Abstract |
Insulin like growth factor receptor (IGF-1R) targeting became one of the most investigated areas in anticancer drug development during the last decade. Strategies aiming to block IGF-1R activity include monoclonal antibodies, tyrosine kinase inhibitors and anti-ligands antibodies. Initial enthusiasm quickly encountered challenges. Unfortunately the validation of the efficacy of IGF-1R targeted agents in large clinical trials failed, however anecdotal single agent activity was seen in early studies. Consequently, questions regarding the selection of right target population and the appropriate trial design are arising. Despite the plethora of clinical trials conducted no predictive biomarker has been validated so far and resistance mechanisms to IGF-1R inhibitors remain unclear. The other issue to be addressed is how to best combine IGF-1R inhibitors with other therapeutic approaches. This review highlights the most relevant clinical data emphasizing the main tumor types where IGF-1R inhibition showed potential interest. We also tried to extract based on clinical and translational data some candidate biomarkers that could help better to select patient population who potentially could benefit most from this therapeutic approach. |
Mendeley readers
The data shown below were compiled from readership statistics for 50 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Germany | 1 | 2% |
| Unknown | 48 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 16 | 32% |
| Student > Ph. D. Student | 10 | 20% |
| Student > Bachelor | 5 | 10% |
| Student > Doctoral Student | 4 | 8% |
| Student > Master | 3 | 6% |
| Other | 3 | 6% |
| Unknown | 9 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 13 | 26% |
| Agricultural and Biological Sciences | 11 | 22% |
| Biochemistry, Genetics and Molecular Biology | 5 | 10% |
| Psychology | 2 | 4% |
| Immunology and Microbiology | 2 | 4% |
| Other | 5 | 10% |
| Unknown | 12 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 January 2023.
All research outputs
#2,221,398
of 23,507,888 outputs
Outputs from Investigational New Drugs
#45
of 1,197 outputs
Outputs of similar age
#13,319
of 158,135 outputs
Outputs of similar age from Investigational New Drugs
#1
of 10 outputs
Altmetric has tracked 23,507,888 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,197 research outputs from this source. They receive a mean Attention Score of 4.8. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 158,135 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them